26 February 2014 - Some patients with an aggressive type of non-Hodgkin's lymphoma - a cancer that develops in the body's immune system - will have the option of receiving a new treatment funded by the NHS following new guidance from NICE.
NICE recommends pixantrone monotherapy (Pixuvri, made by Cell Therapeutics) for people with aggressive non-Hodgkin's B-cell lymphoma whose disease has either returned after treatment (relapsed) or become resistant to current therapy (refractory) and:

• have previously been treated with the drug rituximab (MabThera) and
• are receiving third or fourth line treatment and
• if the manufacturer provides pixantrone at a discounted rate as agreed with the Department of Health.

For more details, go to: http://www.nice.org.uk/newsroom/pressreleases/NICERecommendsNHSFundingNewCancerTreatment.jsp